应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
NTLA Intellia Therapeutics Inc
休市中 07-11 16:00:00 EDT
11.54
-0.62
-5.14%
盘后
11.55
+0.02
+0.13%
19:47 EDT
最高
12.13
最低
11.27
成交量
373.07万
今开
12.01
昨收
12.16
日振幅
7.03%
总市值
11.95亿
流通市值
11.35亿
总股本
1.04亿
成交额
4,347万
换手率
3.79%
流通股本
9,837万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Intellia Therapeutics, Inc.盘中异动 急速拉升5.10%
市场透视 · 06-27
Intellia Therapeutics, Inc.盘中异动 急速拉升5.10%
加拿大投资银行集团:维持Intellia Therapeutics(NTLA.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至54.00美元。
金融界 · 06-03
加拿大投资银行集团:维持Intellia Therapeutics(NTLA.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至54.00美元。
Intellia Therapeutics, Inc.盘中异动 早盘股价大跌5.39%
市场透视 · 05-23
Intellia Therapeutics, Inc.盘中异动 早盘股价大跌5.39%
Intellia Therapeutics, Inc.盘中异动 下午盘股价大跌5.05%
市场透视 · 05-21
Intellia Therapeutics, Inc.盘中异动 下午盘股价大跌5.05%
Intellia Therapeutics, Inc.盘中异动 大幅上涨5.19%报9.53美元
市场透视 · 05-20
Intellia Therapeutics, Inc.盘中异动 大幅上涨5.19%报9.53美元
HC Wainwright & Co.:重申Intellia Therapeutics评级
证券之星 · 05-20
HC Wainwright & Co.:重申Intellia Therapeutics评级
Intellia Therapeutics, Inc.盘中异动 股价大涨5.06%报8.93美元
市场透视 · 05-19
Intellia Therapeutics, Inc.盘中异动 股价大涨5.06%报8.93美元
Intellia Therapeutics, Inc.2025财年第一财季实现净利润-1.14亿美元,同比减少6.54%
市场透视 · 05-17
Intellia Therapeutics, Inc.2025财年第一财季实现净利润-1.14亿美元,同比减少6.54%
Intellia Therapeutics, Inc.盘中异动 大幅拉升5.02%报8.48美元
市场透视 · 05-16
Intellia Therapeutics, Inc.盘中异动 大幅拉升5.02%报8.48美元
Intellia Therapeutics, Inc.盘中异动 急速下挫5.05%
市场透视 · 05-14
Intellia Therapeutics, Inc.盘中异动 急速下挫5.05%
花旗:维持Intellia Therapeutics(NTLA.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至10.00美元。
金融界 · 05-09
花旗:维持Intellia Therapeutics(NTLA.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至10.00美元。
Intellia Therapeutics, Inc.盘中异动 快速上涨5.07%报8.70美元
市场透视 · 05-09
Intellia Therapeutics, Inc.盘中异动 快速上涨5.07%报8.70美元
异动解读 | 基因编辑公司Intellia Therapeutics盘中大涨10.84%,季度业绩超预期
异动解读 · 05-08
异动解读 | 基因编辑公司Intellia Therapeutics盘中大涨10.84%,季度业绩超预期
Intellia Therapeutics, Inc.盘中异动 股价大涨10.97%
市场透视 · 05-08
Intellia Therapeutics, Inc.盘中异动 股价大涨10.97%
Intellia Therapeutics, Inc.盘中异动 股价大跌5.09%报8.01美元
市场透视 · 05-06
Intellia Therapeutics, Inc.盘中异动 股价大跌5.09%报8.01美元
Intellia Therapeutics, Inc.盘中异动 急速上涨5.09%
市场透视 · 05-02
Intellia Therapeutics, Inc.盘中异动 急速上涨5.09%
Intellia Therapeutics, Inc.盘中异动 临近午盘大幅上涨5.00%报8.61美元
市场透视 · 04-30
Intellia Therapeutics, Inc.盘中异动 临近午盘大幅上涨5.00%报8.61美元
Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报8.73美元
市场透视 · 04-28
Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报8.73美元
Intellia Therapeutics, Inc.盘中异动 大幅拉升5.17%
市场透视 · 04-23
Intellia Therapeutics, Inc.盘中异动 大幅拉升5.17%
Intellia Therapeutics, Inc.盘中异动 下午盘股价大涨5.11%
市场透视 · 04-22
Intellia Therapeutics, Inc.盘中异动 下午盘股价大涨5.11%
加载更多
公司概况
公司名称:
Intellia Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司,专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用,发展有潜能的新一代治疗产品。
发行价格:
--
{"stockData":{"symbol":"NTLA","market":"US","secType":"STK","nameCN":"Intellia Therapeutics Inc","latestPrice":11.535,"timestamp":1752264000000,"preClose":12.16,"halted":0,"volume":3730711,"hourTrading":{"tag":"盘后","latestPrice":11.55,"preClose":11.535,"latestTime":"19:47 EDT","volume":83373,"amount":961304.6318,"timestamp":1752277627078},"delay":0,"floatShares":98365722,"shares":103583394,"eps":-5.214891,"marketStatus":"休市中","change":-0.625,"latestTime":"07-11 16:00:00 EDT","open":12.01,"high":12.125,"low":11.27,"amount":43472721.764104,"amplitude":0.070313,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.214891,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1462507200000,"exchange":"NASDAQ","adjPreClose":12.16,"preHourTrading":{"tag":"盘前","latestPrice":12.03,"preClose":12.16,"latestTime":"09:29 EDT","volume":6205,"amount":74653.813175,"timestamp":1752240599999},"postHourTrading":{"tag":"盘后","latestPrice":11.55,"preClose":11.535,"latestTime":"19:47 EDT","volume":83373,"amount":961304.6318,"timestamp":1752277627078},"volumeRatio":0.7719670267694807,"impliedVol":0.7885,"impliedVolPercentile":0.28},"requestUrl":"/m/hq/s/NTLA","defaultTab":"news","newsList":[{"id":"2546422837","title":"Intellia Therapeutics, Inc.盘中异动 急速拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546422837","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546422837?lang=zh_cn&edition=full","pubTime":"2025-06-27 22:09","pubTimestamp":1751033374,"startTime":"0","endTime":"0","summary":"北京时间2025年06月27日22时09分,Intellia Therapeutics, Inc.股票出现异动,股价快速拉升5.10%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.24%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627220934a4c1696d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627220934a4c1696d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4535","NTLA","BK4556","BK4139","BK4588","LU1861558580.USD","LENZ","BK4007","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2540004776","title":"加拿大投资银行集团:维持Intellia Therapeutics(NTLA.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至54.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2540004776","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540004776?lang=zh_cn&edition=full","pubTime":"2025-06-03 19:41","pubTimestamp":1748950911,"startTime":"0","endTime":"0","summary":"加拿大投资银行集团:维持Intellia Therapeutics(NTLA.US)评级,由买入调整至买入评级, 目标价由74.00美元调整至54.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/03194150837064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2537483134","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大跌5.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537483134","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537483134?lang=zh_cn&edition=full","pubTime":"2025-05-23 21:31","pubTimestamp":1748007070,"startTime":"0","endTime":"0","summary":"北京时间2025年05月23日21时31分,Intellia Therapeutics, Inc.股票出现异动,股价快速跳水5.39%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.84%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。消息层面,截至21时31分,《HC Wainwright & Co.:重申Intellia Therapeutics评级》资讯为影响Intellia Therapeutics, Inc.的重要信息。该信息摘要如下:HC Wainwright&Co.:重申Intellia Therapeutics评级,由买入调整至买入评级,目标价由30.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523213110aa2c981c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523213110aa2c981c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4007","BK4585","LU1861558580.USD","LENZ","BK4539","LU1861559042.SGD","BK4139","NTLA","BK4556","BK4588"],"gpt_icon":0},{"id":"2537958102","title":"Intellia Therapeutics, Inc.盘中异动 下午盘股价大跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537958102","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537958102?lang=zh_cn&edition=full","pubTime":"2025-05-22 01:20","pubTimestamp":1747848015,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日01时20分,Intellia Therapeutics, Inc.股票出现波动,股价大幅跳水5.05%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.00%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。消息层面,截至01时20分,《HC Wainwright & Co.:重申Intellia Therapeutics评级》资讯为影响Intellia Therapeutics, Inc.的重要信息。该信息摘要如下:HC Wainwright&Co.:重申Intellia Therapeutics评级,由买入调整至买入评级,目标价由30.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522012016aa2c95b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250522012016aa2c95b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4007","LU1861558580.USD","BK4588","BK4139","LU1861559042.SGD","LENZ","BK4556","BK4585","NTLA","BK4539"],"gpt_icon":0},{"id":"2536641858","title":"Intellia Therapeutics, Inc.盘中异动 大幅上涨5.19%报9.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536641858","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536641858?lang=zh_cn&edition=full","pubTime":"2025-05-20 23:17","pubTimestamp":1747754275,"startTime":"0","endTime":"0","summary":"北京时间2025年05月20日23时17分,Intellia Therapeutics, Inc.股票出现异动,股价快速拉升5.19%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.56%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。消息层面,截至23时17分,《HC Wainwright & Co.:重申Intellia Therapeutics评级》资讯为影响Intellia Therapeutics, Inc.的重要信息。该信息摘要如下:HC Wainwright&Co.:重申Intellia Therapeutics评级,由买入调整至买入评级,目标价由30.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520231755975faa64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520231755975faa64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4556","BK4007","BK4535","BK4585","LU1861558580.USD","LU1861559042.SGD","BK4588","BK4139","NTLA","LENZ"],"gpt_icon":0},{"id":"2536614445","title":"HC Wainwright & Co.:重申Intellia Therapeutics评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2536614445","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536614445?lang=zh_cn&edition=full","pubTime":"2025-05-20 19:23","pubTimestamp":1747740197,"startTime":"0","endTime":"0","summary":"HC Wainwright&Co.:重申Intellia Therapeutics评级,由买入调整至买入评级,目标价由30.00美元调整至30.00美元。Intellia Therapeutics公司简介:Intellia Therapeutics是一家基因编辑公司,致力于开发基于Crispr/Cas9的疗法。Crispr/Cas9是Clustered Regularly Interspaced Short Palindromic Repeats/Crispr-associated protein9的缩写,是一种精确改变基因组DNA特定序列的革命性技术。Intellia致力于利用这项技术治疗基因定义的疾病。Intellia已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜Regeneron和宽膜Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520193558a6e603b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250520193558a6e603b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NTLA"],"gpt_icon":0},{"id":"2536824680","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨5.06%报8.93美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536824680","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536824680?lang=zh_cn&edition=full","pubTime":"2025-05-19 21:34","pubTimestamp":1747661695,"startTime":"0","endTime":"0","summary":"北京时间2025年05月19日21时34分,Intellia Therapeutics, Inc.股票出现波动,股价急速拉升5.06%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.59%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519213455a6e4d108&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519213455a6e4d108&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","NTLA","BK4539","BK4588","BK4535","LU1861559042.SGD","BK4585","LU1861558580.USD","LENZ","BK4556"],"gpt_icon":0},{"id":"2536202584","title":"Intellia Therapeutics, Inc.2025财年第一财季实现净利润-1.14亿美元,同比减少6.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536202584","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536202584?lang=zh_cn&edition=full","pubTime":"2025-05-18 00:00","pubTimestamp":1747497630,"startTime":"0","endTime":"0","summary":"5月18日,Intellia Therapeutics, Inc.公布财报,公告显示公司2025财年第一财季净利润为-1.14亿美元,同比减少6.54%;其中营业收入为16.63百万美元,同比减少42.54%,每股基本收益为-1.10美元。从资产负债表来看,Intellia Therapeutics, Inc.总负债2.06亿美元,其中短期债务38.76百万美元,资产负债比为4.79,流动比率为4.88。机构评级:截至2025年5月18日,当前有25家机构对Intellia Therapeutics, Inc.目标价做出预测,其中目标均价为38.68美元,其中最低目标价为8.00美元,最高目标价为106.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000212a6e2d83d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250518000212a6e2d83d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2536340531","title":"Intellia Therapeutics, Inc.盘中异动 大幅拉升5.02%报8.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2536340531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536340531?lang=zh_cn&edition=full","pubTime":"2025-05-17 03:55","pubTimestamp":1747425331,"startTime":"0","endTime":"0","summary":"北京时间2025年05月17日03时55分,Intellia Therapeutics, Inc.股票出现波动,股价大幅上涨5.02%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.44%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517035531975c1606&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250517035531975c1606&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4535","BK4539","LU1861558580.USD","LU1861559042.SGD","BK4007","LENZ","BK4585","BK4588","NTLA","BK4556"],"gpt_icon":0},{"id":"2535074257","title":"Intellia Therapeutics, Inc.盘中异动 急速下挫5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535074257","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535074257?lang=zh_cn&edition=full","pubTime":"2025-05-14 23:28","pubTimestamp":1747236514,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日23时28分,Intellia Therapeutics, Inc.股票出现异动,股价快速跳水5.05%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.21%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051423283497599c00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051423283497599c00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861559042.SGD","BK4007","BK4139","NTLA","BK4556","BK4588","BK4585","BK4539","LENZ","BK4535","LU1861558580.USD"],"gpt_icon":0},{"id":"2534435702","title":"花旗:维持Intellia Therapeutics(NTLA.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至10.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534435702","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534435702?lang=zh_cn&edition=full","pubTime":"2025-05-09 22:27","pubTimestamp":1746800864,"startTime":"0","endTime":"0","summary":"花旗:维持Intellia Therapeutics(NTLA.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至10.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/09222750280236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NTLA","LENZ"],"gpt_icon":0},{"id":"2534480404","title":"Intellia Therapeutics, Inc.盘中异动 快速上涨5.07%报8.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534480404","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534480404?lang=zh_cn&edition=full","pubTime":"2025-05-09 21:45","pubTimestamp":1746798339,"startTime":"0","endTime":"0","summary":"北京时间2025年05月09日21时45分,Intellia Therapeutics, Inc.股票出现异动,股价急速上涨5.07%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.33%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509214540aa2c890b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509214540aa2c890b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","LENZ","LU1861559042.SGD","BK4139","BK4585","NTLA","BK4588","BK4539","BK4007","LU1861558580.USD","BK4556"],"gpt_icon":0},{"id":"1104509591","title":"异动解读 | 基因编辑公司Intellia Therapeutics盘中大涨10.84%,季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1104509591","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104509591?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:57","pubTimestamp":1746712626,"startTime":"0","endTime":"0","summary":"基因编辑技术公司Intellia Therapeutics Inc今日盘中大涨10.84%,引发市场关注。该公司股价强劲上涨主要受到其最新公布的季度财报超出市场预期的推动。根据Intellia Therapeutics发布的财报显示,截至3月31日的季度调整后每股亏损为1.10美元,优于分析师平均预期的每股亏损1.28美元。公司营收达到1663万美元,同比下降42.5%,但仍大幅超过分析师预期的1187万美元。值得注意的是,尽管Intellia Therapeutics本季度仍然处于亏损状态,但其亏损幅度低于预期,显示出公司在财务管理方面的改善。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 基因编辑公司Intellia Therapeutics盘中大涨10.84%,季度业绩超预期","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTLA"],"gpt_icon":0},{"id":"2533136958","title":"Intellia Therapeutics, Inc.盘中异动 股价大涨10.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533136958","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533136958?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:32","pubTimestamp":1746711130,"startTime":"0","endTime":"0","summary":"北京时间2025年05月08日21时32分,Intellia Therapeutics, Inc.股票出现异动,股价快速上涨10.97%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为1.98%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508213210a6d7c3b4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508213210a6d7c3b4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NTLA","BK4007","BK4588","LU1861558580.USD","BK4535","LENZ","BK4139","LU1861559042.SGD","BK4556","BK4585"],"gpt_icon":0},{"id":"2533551506","title":"Intellia Therapeutics, Inc.盘中异动 股价大跌5.09%报8.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533551506","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533551506?lang=zh_cn&edition=full","pubTime":"2025-05-06 22:34","pubTimestamp":1746542056,"startTime":"0","endTime":"0","summary":"北京时间2025年05月06日22时34分,Intellia Therapeutics, Inc.股票出现异动,股价急速下挫5.09%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为4.20%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506223416aa2c8486&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250506223416aa2c8486&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4535","LENZ","LU1861559042.SGD","BK4556","LU1861558580.USD","BK4007","BK4588","NTLA","BK4139"],"gpt_icon":0},{"id":"2532823096","title":"Intellia Therapeutics, Inc.盘中异动 急速上涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532823096","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532823096?lang=zh_cn&edition=full","pubTime":"2025-05-02 22:36","pubTimestamp":1746196609,"startTime":"0","endTime":"0","summary":"北京时间2025年05月02日22时36分,Intellia Therapeutics, Inc.股票出现波动,股价快速上涨5.09%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.70%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502223649a6d1282e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502223649a6d1282e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4535","BK4588","BK4556","BK4007","LU1861558580.USD","NTLA","BK4139","BK4585","LU1861559042.SGD"],"gpt_icon":0},{"id":"2532654910","title":"Intellia Therapeutics, Inc.盘中异动 临近午盘大幅上涨5.00%报8.61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532654910","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532654910?lang=zh_cn&edition=full","pubTime":"2025-04-30 23:50","pubTimestamp":1746028250,"startTime":"0","endTime":"0","summary":"北京时间2025年04月30日23时50分,Intellia Therapeutics, Inc.股票出现波动,股价急速拉升5.00%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.96%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430235050a6cf053c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430235050a6cf053c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","LU1861559042.SGD","BK4585","BK4556","LENZ","BK4588","NTLA","BK4139","LU1861558580.USD","BK4007"],"gpt_icon":0},{"id":"2530386132","title":"Intellia Therapeutics, Inc.盘中异动 早盘股价大涨5.10%报8.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530386132","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530386132?lang=zh_cn&edition=full","pubTime":"2025-04-28 21:42","pubTimestamp":1745847770,"startTime":"0","endTime":"0","summary":"北京时间2025年04月28日21时42分,Intellia Therapeutics, Inc.股票出现波动,股价急速拉升5.10%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.64%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428214250a46a9141&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250428214250a46a9141&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","LU1861558580.USD","BK4556","BK4007","BK4535","NTLA","BK4585","BK4588","LU1861559042.SGD","BK4139"],"gpt_icon":0},{"id":"2529268787","title":"Intellia Therapeutics, Inc.盘中异动 大幅拉升5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529268787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529268787?lang=zh_cn&edition=full","pubTime":"2025-04-23 21:31","pubTimestamp":1745415061,"startTime":"0","endTime":"0","summary":"北京时间2025年04月23日21时31分,Intellia Therapeutics, Inc.股票出现波动,股价快速上涨5.17%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423213101a463f8f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423213101a463f8f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LENZ","BK4007","LU1861558580.USD","NTLA","BK4535","BK4556","BK4588","BK4139","LU1861559042.SGD"],"gpt_icon":0},{"id":"2529558925","title":"Intellia Therapeutics, Inc.盘中异动 下午盘股价大涨5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529558925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529558925?lang=zh_cn&edition=full","pubTime":"2025-04-23 02:28","pubTimestamp":1745346519,"startTime":"0","endTime":"0","summary":"北京时间2025年04月23日02时28分,Intellia Therapeutics, Inc.股票出现波动,股价急速上涨5.11%。Intellia Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为1.99%。Intellia Therapeutics, Inc.公司简介:Intellia Therapeutics 是一家基因编辑公司,致力于开发基于 Crispr/Cas9 的疗法。Intellia 致力于利用这项技术治疗基因定义的疾病。Intellia 已与多家公司建立了合作关系,以推进其产品线的发展,其中包括窄膜 Regeneron 和宽膜 Novartis。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423022839a462ce50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250423022839a462ce50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1861558580.USD","BK4139","LU1861559042.SGD","BK4588","BK4556","NTLA","BK4007","BK4535","BK4585","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.intelliatx.com","stockEarnings":[{"period":"1week","weight":0.074},{"period":"1month","weight":0.3781},{"period":"3month","weight":0.5567},{"period":"6month","weight":0.1309},{"period":"1year","weight":-0.5317},{"period":"ytd","weight":-0.0107}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司,专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用,发展有潜能的新一代治疗产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.000449},{"month":2,"riseRate":0.666667,"avgChangeRate":0.066917},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.068465},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.038358},{"month":5,"riseRate":0.222222,"avgChangeRate":0.002269},{"month":6,"riseRate":0.9,"avgChangeRate":0.229655},{"month":7,"riseRate":0.6,"avgChangeRate":0.043076},{"month":8,"riseRate":0.555556,"avgChangeRate":0.026121},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.069902},{"month":10,"riseRate":0.222222,"avgChangeRate":-0.087409},{"month":11,"riseRate":0.666667,"avgChangeRate":0.118994},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.093181}],"exchange":"NASDAQ","name":"Intellia Therapeutics Inc","nameEN":"Intellia Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Intellia Therapeutics Inc,NTLA,Intellia Therapeutics Inc股票,Intellia Therapeutics Inc股票老虎,Intellia Therapeutics Inc股票老虎国际,Intellia Therapeutics Inc行情,Intellia Therapeutics Inc股票行情,Intellia Therapeutics Inc股价,Intellia Therapeutics Inc股市,Intellia Therapeutics Inc股票价格,Intellia Therapeutics Inc股票交易,Intellia Therapeutics Inc股票购买,Intellia Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Intellia Therapeutics Inc(NTLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Intellia Therapeutics Inc(NTLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}